Pay in 4 interest-free payments of $7.30 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Two registered trials (one Phase 1 with no posted results, one Phase 2 still recruiting) and three small uncontrolled reports covering fewer than 30 subjects total
For injectable peptides, bioavailability approaches 100% because the compound enters the bloodstream directly
The format suits combined-peptide research at half the standalone-vial loading of each component, engaging two non-overlapping mechanism niches: VEGFR2-Akt-eNOS vascular signalling from BPC-157 and parent-Thymosin--4 actin-cytoskeleton dynamics from TB-500
Because research materials cannot be accepted back into controlled inventory after shipment, BGX does not accept returns or provide refunds, exchanges, or store credit except where required by applicable law or expressly stated below
US$ 21.25
US$ 27.25
US$ 29.41
US$ 22.76
US$ 26.10
US$ 22.41
US$ 26.72
